Table 3.
SCORE | −1 | 0 | 1 | 2 | OVERALL RESPONSE (1 + 2) |
---|---|---|---|---|---|
Placebo group | 3/18 | 12/18 | 2/18 | 1/18 | 3/18 |
Cyclic pain | 16.6% | 66.7% | 11.1% | 5.5% | 16.6% |
Placebo group | 2/12 | 8/12 | 2/12 | 0/12 | 2/12 |
Noncyclic pain | 16.6% | 66.7% | 16.6% | 16.6% | |
Placebo group | 2/7 | 4/7 | 1/7 | 0/7 | 1/7 |
Musculoskeletal ache | 28,8% | 57% | 14.2% | 14.2% | |
GLOBAL | 5/30 | 20/30 | 4/30 | 1/30 | 5/30 |
(Cyclic + Noncyclic) | 16.6% | 66.7% | 13.3% | 3.3% | 16.6% |
Experimental group | 2/19 | 7/19 | 3/19 | 7/19 | 10/19 |
Cyclic pain | 10.5% | 36.8% | 15.8% | 36.8% | 52.6% |
Experimental group | 2/13 | 3/13 | 6/13 | 2/13 | 8/13 |
Noncyclic pain | 15.4% | 23% | 46.1% | 15.4% | 61.5% |
Experimental group | 1/7 | 3/7 | 3/7 | 0/7 | 3/7 |
Musculoskeletal ache | 14.2% | 42.9% | 42.9% | 42.9% | |
GLOBAL | 4/32 | 10/32 | 9/32 | 9/32 | 18/32 |
(Cyclic + Noncyclic) | 12.5% | 31.2% | 28.1% | 28.1% | 56.2% |